Meningiomas

Current Treatment Options in Neurology

Volumn 10, Issue 4, 2008, Pages 315-320

  Grimm, Sean ^a   Raizer, Jeffrey J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMINOPHYLLINE; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACARBAZINE; DOXORUBICIN; ERLOTINIB; GEFITINIB; HYDROXYUREA; IFOSFAMIDE; IMATINIB; INSULIN; IRINOTECAN; MESNA; MIFEPRISTONE; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; THEOPHYLLINE; UNINDEXED DRUG; VATALANIB; VINCRISTINE; WARFARIN;

ABDOMINAL PAIN; AGEUSIA; ALOPECIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN SURGERY; BREAST TENDERNESS; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CRANIOTOMY; DIARRHEA; DIET; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ERYTHEMA; EXERCISE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FLU LIKE SYNDROME; GENETIC PREDISPOSITION; GYNECOMASTIA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; LIFESTYLE; LIVER DYSFUNCTION; MALIGNANT MENINGIOMA; MENINGIOMA; MENTAL DISEASE; MORBIDITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOTHERAPY; RADIATION NECROSIS; RADIOSURGERY; REVIEW; RISK FACTOR; SPEECH THERAPY; STROKE; SURGICAL INFECTION; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT; WALKING AID;

EID: 58649115577     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0034-9     Document Type: Review

References (28)

1. CBTRUS: Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Hinsdale, IL: Central Brain Tumor Registry of the United States, 2005. Available at http://www.cbtrus.org/reports//2005-2006/ 2006report.pdf. Accessed March 20, 2008.
2. Perry A, Dehner LP: Meningeal tumors of childhood and infancy. An update and literature review. Brain Pathol 2003, 13:386-408.
3. Lamszus K, Vahldiek F, Mautner VF, et al.: Allelic losses in neurofibromatosis 2-associated meningiomas. J Neuropathol Exp Neurol 2000, 59:504-512.
4. Ruttledge MH, Sarrazin J, Rangaratnam S, et al.: Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994, 6:180-184.
5. Zang KA: Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 2001, 93:207-220.
6. Bondy M, Ligon BL: Epidemiology and etiology of intracranial meningiomas: A review. J Neurooncol 1996, 29:197-205.
7. Yano S, Kuratsu J: Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg 2006, 105:538-543.
8. Herscovici Z, Rappaport Z, Sulkes J, et al.: Natural history of conservatively treated meningiomas. Neurology 2004, 63:1133-1134.
9. Jaaskelainen J: Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 1986, 26:461-469.
10. MirimaAoff RO, Dosoretz DE, Linggood RM, et al.: Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985, 62:18-24.
11. Rogers L, Mehta M: Role of radiation therapy in treating intracranial meningiomas. Neurosurg Focus 2007, 23:E4.
12. Goldsmith BJ, Wara WM, Wilson CB, Larson DA: Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994, 80:195-201.
13. Milker-Zabel S, Zabel A, Schulz-Ertner D, et al.: Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: Long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005, 61:809-816.
14. DiBiase SJ, Kwok Y, Yovino S, et al.: Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas. Int J Radiat Oncol Biol Phys 2004, 60:1515-1519.
15. Grunberg SM, Weiss MH: Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 1990, 8:61-65.
16. Goodwin JW, Crowley J, Eyre HJ, et al.: A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study. J Neurooncol 1993, 15:75-77.
17. Grunberg SM, Weiss MH, Spitz IM, et al.: Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991, 74:861-866.
18. Grunberg SM, Rankin C, Townsend J, et al.: Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma [abstract]. Proc Am Soc Clin Oncol 2001, 20: Abstract 222.
19. Chamberlain MC, Slantz MJ, Fadul CE: Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007, 69:969-973.
20. Chamberlain MC: Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 1996, 84:733-736.
21. Kyritsis AP: Chemotherapy for meningiomas. J Neurooncol 1996, 29:269-272.
22. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 2006, 78:271-276.
23. Chamberlain MC, Tsao-Wei DD, Groshen S: Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004, 62:1210-1212.
24. Mason WP, Gentili F, Macdonald DR, et al.: Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 2002, 97:341-346.
25. Newton HB, Scott SR, Volpi C: Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 2004, 18:495-499.
26. Norden AD, Drappatz J, Wen PY: Targeted drug therapy for meningiomas. Neurosurg Focus 2007, 23:E12.
27. Kaba SE, DeMonte F, Bruner JM, et al.: The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997, 40:271-275.
28. Wen PY, Yung WKA, Lamborn K, et al.: Phase II study of imatinib mesylate (STI571) for patients with recurrent meningiomas (NABTC 01-08) [abstract TA-66]. Neuro-Oncology 2006, 8:454.